Our Product Pipeline


Talaris Therapeutics is working rapidly to bring its revolutionary cell therapy technology to other patients beyond living donor kidney transplants.

In addition to our recently launched Phase 3 trial in living donor kidney transplant patients, we plan to initiate two Phase 2 trials in 2020: (1) to evaluate the safety and potential of our therapy to restore immune tolerance in patients suffering from a severe auto-immune or immune-mediated disorder, and (2) to evaluate our therapy’s potential to enable patients who have previously received a living donor kidney transplant to be weaned off their chronic immunosuppression medications. We also plan to explore the potential of our therapy to benefit patients who receive an organ transplant from a deceased donor.